Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Mult Scler
; 28(7): 1138-1145, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1861995
ABSTRACT
BACKGROUND:
The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear.OBJECTIVES:
We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID).METHODS:
Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers.RESULTS:
457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies.CONCLUSION:
Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Mult Scler
Journal subject:
Neurology
Year:
2022
Document Type:
Article
Affiliation country:
13524585221089540
Similar
MEDLINE
...
LILACS
LIS